Is Niagen Bioscience, Inc. (NAGE) overvalued? · P/E 59, rev $99.6M
Niagen Bioscience, Inc. (NAGE) is a biotechnology company listed on US.
This page asks whether Niagen Bioscience, Inc. (NAGE) looks expensive on cached numbers — not a short thesis.
Latest reported NAGE revenue for 2024-12-31 was $99.6M. Net income was $8.6M. Revenue was up 19.2% from 2023-12-31 to 2024-12-31. NAGE currently screens at market cap $836.5M and trailing P/E 59.0.
NAGE currently screens at market cap $836.5M and trailing P/E 59.0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NAGE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NAGE stock page for the full model, not this heading.
Not investment advice.